Vaxart, Inc. – Press Releases

Search

Year

August 08, 2022

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new omicron variants of concern Positive data from norovirus trial in elderly show similar immunogenicity to younger adults Ended second quarter with

August 08, 2022

PDF Version

Vaxart Appoints W. Mark Watson to its Board of Directors

Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart , Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effective August 4, 2022 . Mr.

August 05, 2022

PDF Version

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

All six proposals approved in the 2022 Proxy Statement Vote strengthens the Company as it progresses its oral vaccine programs SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2022 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) announced today that at its reconvened Annual Meeting of Stockholders on August

July 28, 2022

PDF Version

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on Monday, August 8,

July 27, 2022

PDF Version

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif. , July 27, 2022 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) today urged its stockholders of record on

July 20, 2022

PDF Version

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it develops additional vaccine candidates SOUTH SAN FRANCISCO, Calif.

July 14, 2022

PDF Version

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

SOUTH SAN FRANCISCO, Calif. , July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker , SVP and Chief Scientific Officer, and Dr. Rebecca Flitter , Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development

July 01, 2022

PDF Version

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif. , July 01, 2022 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) today urges its stockholders

June 30, 2022

PDF Version

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

Model will be used in Vaxart’s Phase II Omicron Challenge Trial Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study SOUTH SAN FRANCISCO, Calif. , June 30, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced an agreement with hVIVO Services

June 16, 2022

PDF Version

Vaxart to Host Investor Q&A Webcast

Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , June 16, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will host a question-and-answer webcast with

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Press Releases.

Search